21st Austria weekly - Valneva EVN 25/02/2022 [pic1]Valneva: Valneva SE an Austrian/French specialty vaccine company today announced that the Committee for Medicinal Products Human Use CHMP of European Medicines Agency EMA has provided initial assessment Valneva’s inactivated adjuvanted COVID-19
21st Austria weekly - Valneva EVN 25/02/2022 [pic1]Valneva: Valneva SE an Austrian/French specialty vaccine company today announced that the Committee for Medicinal Products Human Use CHMP of European Medicines Agency EMA has provided initial assessment Valneva’s inactivated adjuvanted COVID-19
21st Austria weekly - Valneva 10/08/2021 [pic1]Valneva: Valneva’s total revenues were Euro 47.5 mn in the first half of 2021 compared to 47.9 2020. Product sales declined by 22.4% 31.8 40.9 recorded an operating loss 86.2 21.9 EBITDA was €80.1 million 17.2 In 2021 generated a net amounting 86.4 25.6 Thomas Lingelbach Chief Executive Officer commented “Valneva is continuing hit its major R&D objectives. We have just reported great results world’s ever Phase
21st Austria weekly - Valneva S Immo 03/06/2021 [pic1]Valneva: Austrian/French specialty vaccine company Valneva announced that it has completed recruitment for the pivotal Phase 3 trial of its inactivated adjuvanted COVID-19 candidate VLA2001. Over 4 000 volunteers in United Kingdom have been randomized “Cov-Compare” VLA2001-301 which compares Valneva’s SARS-CoV-2 VLA2001 against AstraZeneca’s conditionally approved vaccine Vaxzevria.
31.01.2021
Palfinger: Palfinger, a leading international manufacturer of innovative lifting solutions, is currently the target of an ongoing global cyber attack. IT infrastructure is disrupted at the moment (including sending and receiving emails, ERP systems). A large proportion of the group s worldwide locations are affected. It is not possible to estimate the precise extent and duration of the attack or its consequences at this time. Work is being carried out intensively on a solution , the company stated.
Palfinger: weekly performance:
-5.02%
Valneva: Valneva, an Austrian/French specialty vaccine company, and Instituto Butantan, producer of immunobiologic products, today announced the signing of definitive agreements for the development, manufacturing and marketing of Valneva’s single-shot chikungunya vaccine, VLA1553, in Low and Middle Income Countries (LMICs). This finalization follows the signing of a binding term sheet in May 2020. The collaboration falls within t